Deficiency in POLE Exonuclease Causes Synthetic Lethality in Highly Aneuploid Cancer Cells

Area of Science:

• Cancer genomics
• Molecular oncology
• Synthetic lethality

Background:

• Aneuploidy is a common feature in cancer, correlating with drug resistance and adverse clinical outcomes.
• Despite its prevalence, effective therapies specifically targeting highly aneuploid tumors remain elusive.

Purpose of the Study:

• To identify potential therapeutic vulnerabilities in highly aneuploid tumors.
• To investigate the relationship between aneuploidy and specific genetic mutations, such as those in POLE.

Main Methods:

• Analysis of comprehensive genomic profiling data from nearly half a million tumor samples.
• Validation using datasets from The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE).
• Probabilistic modeling and functional experiments to assess the impact of POLE mutations on aneuploid cells.

Main Results:

• A significant mutual exclusivity was observed between POLE exonuclease domain mutations and high aneuploidy.
• POLE exonuclease deficiency induces a unique mutation spectrum that can lead to synthetic lethality in aneuploid cells.
• POLE exonuclease activity is critical for the survival of highly aneuploid cancer cells but not diploid cells.

Conclusions:

• Selective inhibition of POLE exonuclease activity presents a potential therapeutic strategy for highly aneuploid cancers.
• This approach leverages a synthetic lethal interaction dependent on both aneuploidy and POLE mutation status.